An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 conse...
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous ...
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior...
Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children
The overarching hypothesis of the ARRC trial is that administration of Azithromycin (AZM) during acute, Respiratory Syncytial Virus (RSV)-induced respiratory failure will be beneficial, mediated throu...
A Study of BLB-201 RSV Vaccine in Infants and Children
This Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 10\^7 PFU) of intranasal BLB-201 (a recomb...
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hemat...
Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
This phase II trial tests how well remdesivir works for treatment of respiratory syncytial virus (RSV) infection of the upper respiratory tract in patients receiving cellular or bispecific antibody th...
Top Cities for RSV Clinical Trials
RSV clinical trials are recruiting across 50 cities. Here are the cities with the most active studies:
About RSV
Respiratory syncytial virus (RSV) is a common respiratory virus that usually causes mild, cold-like symptoms but can be serious in infants, older adults, and immunocompromised individuals. New preventive therapies including monoclonal antibodies and vaccines have recently been approved. Clinical trials continue to investigate improved treatments.
Clinical trials are advancing new treatments for rsv. Currently, 7 studies are recruiting a combined 12,070 participants across the United States. Research is being conducted by 7 organizations including GlaxoSmithKline, Pfizer, ModernaTX, Inc. and 4 others.
2026 RSV Research Landscape
As of March 2026, the rsv clinical trial landscape includes 7 actively recruiting studies across 50 cities in the United States. These studies are collectively seeking 12,070 participants, with an average enrollment target of 1,724 per study.
Research is being led by 7 different organizations, including GlaxoSmithKline, Pfizer, ModernaTX, Inc., University of Alabama at Birmingham, Blue Lake Biotechnology Inc., and 2 others.
Geographically, rsv trials are most concentrated in Birmingham, Alabama (7 trials); Los Angeles, California (4 trials); Mobile, Alabama (2 trials); Oklahoma City, Oklahoma (2 trials); Duarte, California (2 trials) and 7 other cities.
Featured RSV Studies
Highlighted recruiting studies for rsv, selected by enrollment size and research scope.
An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study
The purpose of this study is: * To investigate the optimal timing for revaccination after the initial RSVPreF3 OA vaccine dose, * To evaluate the long-term immune persistence and safety up to 5 consecutive RSV seasons (approximately 60 months) of a single dose of RSVPreF3 OA vaccine, * To give the opportunity to participants who received only placebo in the RSVOA=ADJ- 006 study, to receive a dose...
A Phase 3 Study of Revaccination in Subsequent Pregnancies With Bivalent RSV Vaccine and Duration of Protection of a Single Dose
This study aims to check how safe and well-tolerated a second dose of RSVpreF is when given during later pregnancies, and to see how long the immunity lasts from a single dose given during a previous pregnancy by examining the blood of nonpregnant participants who had the vaccine before.
A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age
The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.
Frequently Asked Questions About RSV Clinical Trials
Are there rsv clinical trials near me?
Yes, there are 7 rsv clinical trials currently recruiting across 50+ cities in the United States, including Birmingham, Alabama; Los Angeles, California; Mobile, Alabama. Browse the studies above to find one at a location convenient for you.
How do I join a rsv clinical trial?
To join a rsv clinical trial: 1) Browse the available studies on this page, 2) Click on a study that interests you, 3) Check the study locations to find a site near you, 4) Review the eligibility criteria, and 5) Contact the study site or complete the eligibility form. The process is free and you can withdraw at any time.
Are rsv clinical trials free?
Yes, participation in rsv clinical trials is free. Study-related treatments, medical tests, and doctor visits are provided at no cost to participants. Many studies also offer compensation for your time and travel expenses.
What types of rsv treatments are being studied?
Current rsv clinical trials are testing a range of approaches. These include new drugs, combination therapies, medical devices, and other interventions sponsored by 7 research organizations.
Is it safe to participate in rsv clinical trials?
Clinical trials are carefully regulated by the FDA and institutional review boards (IRBs). All trials must follow strict safety protocols, and participants receive close medical monitoring throughout the study. You can withdraw from a trial at any time without penalty.
Data updated March 1, 2026 from ClinicalTrials.gov
About This Data
Clinical trial information on this page is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health (NIH) and National Library of Medicine (NLM). Study data is refreshed every hour to ensure accuracy.
Medical Disclaimer: The information provided on this page is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before making decisions about clinical trial participation or changes to your treatment plan.
Page reviewed by the HelloStudys Research Team · Last updated March 1, 2026 · Data from ClinicalTrials.gov